Home >> Pharmaceuticals >> Food & Beverage >>

Pulmonary Hypertension - Global Market Research 2015-2019

Published: Sep-2015 | Format: PDF | Technavio | Number of pages: 65 | Code: MRS - 35113

About pulmonary hypertension

Pulmonary hypertension is a rare disorder that affects the pulmonary arteries carrying deoxygenated blood to the lungs from the heart. The narrowing or blockage of pulmonary arteries will lead to pulmonary hypertension. Symptoms of the disease do not occur until the disease becomes severe. Certain causes of pulmonary hypertension include emphysema, connective tissue disorders, blood clots in lungs, and sleep apnea. Pulmonary hypertension may sometimes lead to several chronic illnesses, such as kidney failure (renal failure), heart failure, aneurysm, heart attack, or, stroke. Endothelin receptor antagonists, prostacyclin analogs, phosphodiesterase inhibitors, and sGC stimulators are popular drug therapeutic classes available for the treatment of pulmonary hypertension. 

Technavio's analysts forecast the global pulmonary hypertension market to grow at a CAGR of 2.92% over the period 2014-2019.

Covered in this report

The report includes the present scenario and the growth prospects of the global pulmonary hypertension market for the period 2015-2019. To calculate the market size, the report considers revenue generated through the sales of various drugs used in the treatment of pulmonary hypertension. 

Technavio's report, Global Pulmonary Hypertension Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. It covers the market size and forecast as well as market segmentation and pipeline landscape. The report includes a discussion of the key vendors operating in this market.

Key vendors
• Actelion
• Bayer
• GlaxoSmithKline
• United Therapeutics

Other prominent vendors
• Aires Pharmaceuticals
• Arena Pharmaceuticals
• Bial
• DEKA
• Dong-A ST
• Gilead
• Merck
• Northern Therapeutics
• Novartis
• Pfizer
• PhaseBio

Key market driver
• Growing incidence of pulmonary hypertension
• For a full, detailed list, view our report

Key market challenge
• Patent expiry
• For a full, detailed list, view our report

Key market trend
• Increased focus on combination therapies
• For a full, detailed list, view our report

Key questions answered in this report
• What will the market size be in 2019 and what will the growth rate be
• What are the key market trends
• What is driving this market
• What are the challenges to market growth
• Who are the key vendors in this market space
• What are the market opportunities and threats faced by the key vendors
• What are the strengths and weaknesses of the key vendors
PART 01: Executive summary
 Highlights

PART 02: Scope of  the report
 Market overview
 Top vendor offerings

PART 03: Market research methodology
 Research methodology
 Economic indicators

PART 04: Introduction
 Key market highlights

PART 05: Market landscape
 Market overview
 Market size and forecast
 Five forces analysis

PART 06: Pipeline portfolio
 Key information of pipeline candidates

PART 07: Market segmentation  by type of formulation
 Oral
 Injection
 Inhalation

PART 08: Market segmentation by mechanism of action
 Endothelin receptor antagonist
 Prostacyclin analogs
 Phosphodiesterase inhibitors
 Soluble guanylate cyclase stimulators

PART 09: Geographical segmentation

PART 10: Market drivers

 Increase in incidence of pulmonary hypertension
 Patient assistance programs
 New disease-modifying therapies
 Unmet medical needs

PART 11: Impact of drivers

PART 12: Market challenges
 Patent expiry
 Poor patient compliance
 Intense competition among vendors

PART 13: Impact of drivers and challenges

PART 14: Market trends
 Increased focus on combination therapies
 Increase in awareness of hypertension
 Strategic alliances

PART 15: Vendor landscape
 Competitive scenario
 Key news
 Mergers and acquisitions
 Market share analysis 2014
 Other prominent vendors

PART 16: Key vendor analysis
 Actelion Pharmaceuticals
 Bayer HealthCare
 GSK
 United Therapeutics

PART 17: Appendix
List of abbreviations

PART 18: Explore Technavio

List of Exhibits 

Exhibit 01: Product offerings
Exhibit 02: Global pulmonary hypertension market: 2014-2019 ($ billions)
Exhibit 03: Five forces analysis
Exhibit 04: Pipeline portfolio
Exhibit 05: Market segmentation by type of formulation
Exhibit 06: Market segmentation by type of formulation 2014
Exhibit 07: Market segmentation by mechanism of action
Exhibit 08: Market segmentation by mechanism of action 2014
Exhibit 09: Market segmentation by region 2014
Exhibit 10: Impact of drivers
Exhibit 11: Revatio sales in the US 2011-2014 ($ millions)
Exhibit 12: Impact of drivers and challenges
Exhibit 13: Actelion Pharmaceuticals : Key takeaways
Exhibit 14: Tracleer: Global sales 2011-2014 ($ billions)
Exhibit 15: Opsumit: Global sales 2013-2015 H1 ($ millions)
Exhibit 16: Ventavis: Global sales 2011-2014 ($ millions)
Exhibit 17: Veletri: Global sales 2011-2014 ($ millions)
Exhibit 18: United Therapeutics: Key takeaways
Exhibit 19: Remodulin: Global sales 2011-2014 ($ millions)
Exhibit 20: Tyvaso: Global sales 2011-2014 ($ millions)
Exhibit 21: Adcirca: Global sales 2011-2014 ($ millions)
Exhibit 22: Orenitram: Global sales 2014-2015 H2 ($ millions)
Exhibit 23: GlaxoSmithKline: Key takeaways
Exhibit 24: Flolan: Global sales 2012-2013 ($ millions)
Exhibit 25: Bayer: Key takeaways
Exhibit 26: Adempas: Global sales 2013-2014 ($ millions)
Exhibit 27: Actelion Pharmaceuticals: Product segmentation
Exhibit 28: Actelion Pharmaceuticals: Business segmentation by revenue 2014
Exhibit 29: Actelion Pharmaceuticals: Business segmentation by revenue 2013 and 2014 ($ millions)
Exhibit 30: Actelion Pharmaceuticals: Geographical segmentation by revenue 2014
Exhibit 31: United Therapeutics: Product segmentation by revenue 2014
Exhibit 32: United Therapeutics: Product segmentation by revenue 2014 ($ millions)
Exhibit 33: United Therapeutics: Geographical segmentation by revenue 2014

                        
            

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode
Single User | $(USD)2500 View Pricing